<DOC>
	<DOCNO>NCT00049439</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine lomustine , etoposide , cyclophosphamide , procarbazine treat patient AIDS-related non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With AIDS-Related Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate , response duration , survival patient AIDS-related non-Hodgkin 's lymphoma treat lomustine , etoposide , cyclophosphamide , procarbazine . - Determine feasibility regimen patient . - Determine clinical toxicity regimen patient . - Assess quality life patient treat regimen . - Determine impact regimen underlie HIV infection patient . OUTLINE : This multicenter study . Patients receive oral lomustine day 1 ( course 1 ) , oral etoposide day 1-3 , oral cyclophosphamide oral procarbazine day 22-26 . Patients may also receive filgrastim ( G-CSF ) subcutaneously day 5-21 28-42 . Treatment repeat every 6 week 2 course absence disease progression unacceptable toxicity . Quality life assess baseline , day 1 22 course , day 84 , every 3 month 1 year . Patients follow day 84 every 3 month . PROJECTED ACCRUAL : A total 66 patient ( 22 United States 44 Africa ) accrue study within 3-4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acquire immune deficiency syndrome Histologically confirmed stage I , II , III , IV intermediate highgrade nonHodgkin 's lymphoma Bcell , Tcell , indeterminate immunologic phenotype Measurable evaluable disease No clinical , radiographic , cytological evidence CNS parenchymal , vitreal , leptomeningeal involvement lymphoma NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 18 ( United States ) 16 ( Africa ) Performance status ECOG 03 Life expectancy At least 6 week Hematopoietic WBC least 1,500/mm3 Platelet count least 50,000/mm3 Hepatic Bilirubin great 3.0 mg/dL Renal Creatinine great 3.0 mg/dL Other Concurrent active infection patient receive treatment allow provide clinical status stable Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy lymphoma Endocrine therapy Not specify Radiotherapy Prior radiotherapy stage I II disease allow provide documentation disease progression Surgery Not specify Other Concurrent antiretroviral therapy ( except zidovudine ) allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
</DOC>